Clinical Trials Using Anti-GITR Agonistic Monoclonal Antibody INCAGN01876

Clinical trials are research studies that involve people. The clinical trials on this list are studying Anti-GITR Agonistic Monoclonal Antibody INCAGN01876. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trial 1 of 1
  • Ragifilimab and Retifanlimab in Combination with Stereotactic Radiosurgery for the Treatment of Recurrent Glioblastoma

    This phase II trial studies the effect of ragifilimab and retifanlimab in combination with stereotactic radiosurgery in treating patients with glioblastoma that has come back (recurrent). Immunotherapy with monoclonal antibodies, such as ragifilimab and retifanlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Stereotactic radiosurgery uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving ragifilimab and retifanlimab together with stereotactic radiosurgery may kill more tumor cells.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania